Activity and Safety of Peptide-based Immunotherapy in an Umbrella Window-of-opportunity Phase II Study in Patients With Squamous Cell Carcinoma of the Head and Neck.

The purpose of this project is to realize a randomized open-label study (EudraCT number: 2020-000120-19) to evaluate the safety and the anti-tumor activity of peptide(s)-based immunotherapy in an umbrella window pre-operative opportunity phase II study in patients with squamous cell carcinoma of the head and neck.

Start Date14 Aug 2020

Sponsor / Collaborator

Cliniques Universitaires Saint-Luc

NCT03850522 / TerminatedPhase 2IIT

Phase IIa Trial of PD-L1 Peptide Vaccination as Monotherapy in High Risk Smoldering Multiple Myeloma

This study is evaluating a new vaccine against PD-L1 as a possible treatment for high-risk smoldering multiple myeloma.

Start Date18 Feb 2019

Sponsor / Collaborator

Herlev Hospital

[+1]

NCT03714529 / CompletedPhase 2IIT

Phase IIa Trial With PD-L1 IO103 Vaccination With Montanide in Patients With Basal Cell Carcinoma

A single center, open-label, phase IIa, single arm, window of opportunity trial with IO103 and Montanide adjuvant in patients with surgically resectable BCC.

Start Date01 Nov 2018

Sponsor / Collaborator

Herlev Hospital

[+1]

100 Clinical Results associated with etimumotide

100 Translational Medicine associated with etimumotide

100 Patents (Medical) associated with etimumotide

Literatures (Medical) associated with etimumotide

01 May 2023·Cancer letters

Active immunization with a structurally aggregated PD-L1 antigen breaks T and B immune tolerance in non-human primates and exhibits in vivo anti-tumoral effects in immunocompetent mouse tumor models

Article

Author: Sanchez-Ramirez, J. ; Bequet-Romero, M. ; Palenzuela, D. ; Canaan-Haden, C. ; Morera-Diaz, Y. ; Gavilondo, J. V. ; Ayala-Avila, M. ; Gonzalez-Moya, I. ; Martinez, R. ; Falcon, V.

Despite the clinical success of the programmed death ligand 1 (PD-L1) blocking therapy in cancer treatment, only a subset of patients exhibits durable responses, therefore further exploration of other immunotherapeutic alternatives are needed. This paper reported the development of the PKPD-L1^Vac vaccine, a new protein vaccine candidate that uses aluminum phosphate as an adjuvant and as an antigen the extracellular domain of human PD-L1 fused to a 47 amino-terminal portion of the LpdA protein from N. meningitides (PKPD-L1). The PKPD-L1 antigen has different physical and biological characteristics than those found in the natural molecule and in others PD-L1 vaccine candidates. The quimeric protein has a reduced binding capacity to the PD-1 and CD80 receptors to decrease their pro-tumoral activity. Besides, the distinctive feature of the PKPD-L1 polypeptide to be structurally aggregated could be desirable for its immunogenic properties. PKPD-L1^Vac elicited anti-PD-L1-specific IgG antibodies and T lymphocyte-mediated immunity in mice and non-human primates. The vaccine administration demonstrated antitumor activity on CT-26 and B16-F10 primary tumor models in mice. Moreover, the immunization with PKPD-L1^Vac increased the tumor-infiltrating lymphocytes and decreased the proportion of CD3⁺CD8⁺PD1^+high anergic T cells in CT-26 tumor tissues, suggesting that the vaccine may remodel the tumor microenvironment. In summary, the PKPD-L1^Vac vaccine exhibits very promising preclinical results and deserves to move forward to a phase I clinical trial.

31 Dec 2022·Oncoimmunology

A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx)

Article

Author: Overholser, Jay ; Ede, Nicholas J. ; Darby, Heather ; Kaumaya, Pravin T.P ; Guo, Linlin

Blockade of checkpoint receptors with monoclonal antibodies against CTLA-4, PD-1 and PD-L1 has shown great clinical success in several cancer subtypes, yielding unprecedented responses albeit a significant number of patients develop resistance and remain refractory. Both PD-1/PD-L1 and HER-2 signaling pathway inhibitors have limited efficacy and exhibits significant toxicities that limit their use. Ongoing clinical studies support the need for rationale combination of immuno-oncology agents to make a significant impact in the lives of cancer patients. We introduce the development of a novel chimeric PD-L1 B-cell peptide epitope vaccine (amino acid 130-147) linked to a "promiscuous" T cell measles virus fusion (MVF) peptide (MVF-PD-L1(130); PDL1-Vaxx) or linked to tetanus toxoid (TT3) TT3-PD-L1 (130) via a linker (GPSL). These vaccine constructs are highly immunogenic and antigenic in several syngeneic animal models. The PD-L1 vaccines elicited high titers of polyclonal antibodies that inhibit tumor growth in multiple syngeneic cancer models, eliciting antibodies of different subtypes IgG1, IgG2a, IgG2b and IgG3, induced PD-1/PD-L1 blockade, decreased proliferation, induced apoptosis and caused ADCC of tumor cells. The PDL1-Vaxx induces similar inhibition of tumor growth versus the standard anti-mouse PD-L1 antibody in both syngeneic BALB/c and C57BL/6J mouse models. The combination of PDL1-Vaxx with HER-2 vaccine B-Vaxx demonstrated synergistic tumor inhibition in D2F2/E2 carcinoma cell line. The anti-PDL1-Vaxx block PD-1/PD-L1 interaction and significantly prolonged anti-tumor responses in multiple syngeneic tumor models. The combination of HER-2 vaccine (B-Vaxx) with either PDL1-Vaxx or PD1-Vaxx demonstrated synergistic tumor inhibition. PDL1-Vaxx is a promising novel safe checkpoint inhibitor vaccine.

01 Apr 2020·Computational biology and chemistryQ4 · BIOLOGY

Designing a potent L1 protein-based HPV peptide vaccine: A bioinformatics approach

Q4 · BIOLOGY

Article

Author: Valadan, Reza ; Pasandi, MarziehSharifi ; Kardan, Mostafa ; Yazdani, Zahra ; Ashrafi, Hossein ; Rafiei, Alireza

BACKGROUND:

Oncogenic human papilloma viruses (HPV) are the cause of various types of cancer, specifically cervical cancer. L1 protein is the main protein of HPV capsid which targeted in many vaccine-producing attempts. However, they have not enough coverage on the various high risk HPV types. Therefore, having a low cost potent HPV vaccine to protect against all members of the α-papillomaviridea family will be promising. In this study, L1 protein-based peptide vaccine was designed using immunoinformatics methods which provides physicochemical properties such as stability in room temperature, potential of antigenicity, non-allergic properties and no requirement with eukaryotic host system.

RESULTS:

The designed vaccine has two HPV conserved epitopes with lengths 18 and 27 amino acids in all members of α-papillomaviridea. These peptides promote humoral and cellular immunity and INF-γ responses. In order to ensure strong induction of immune responses, Flagellin, a Toll like receptor 5(TLR-5) agonist, and a short synthetic toll like receptor 4 (TLR-4) agonist were also joined to the epitopes. Structure of the designed- vaccine was validated using Rampage and ERRAT and a high quality 3D structure of the vaccine protein was provided. Docking studies demonstrated an appropriate and stable interaction between the vaccine and TLR-5.

CONCLUSIONS:

The vaccine is expected to have a high quality structure and suitable properties including high stability, solubility and a high potential to be expressed in E.coli. High potentiality of the vaccine in inducing humoral and cellular immune responses, may be considered as an anti-tumor vaccine.

News (Medical) associated with etimumotide

15 Sep 2024

·www.globenewswire.com

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

-- Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the Head and Neck Cohort -- -- No New Safety Signals or Added Systemic Safety Concerns Observed -- -- Data Presented at the European Society for Medical Oncology (ESMO) Congress -- Sept. 14, 2024 -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines, announced promising data from the Phase 2 basket trial of IO102-IO103, the company’s lead investigational therapeutic cancer vaccine candidate, in combination with Merck’s (known as MSD outside of the United States and Canada) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) (IOB-022/KN-D38) at the 2024 ESMO Congress in Barcelona from September 13-17. The presentation contained clinical and biomarker data from a cohort of patients with recurrent or metastatic (advanced) squamous cell carcinoma of the head and neck (SCCHN) with PD-L1 CPS ≥ 20 (PD-L1 high), contributing to the growing body of research supporting the potential clinical benefit of this combination regimen for these patients. The data from 18 efficacy evaluable patients demonstrated: Achievement of the primary endpoint – confirmed 44.4% overall response rate (ORR) in a PD-L1 high population of patients with SCCHN irrespective of HPV status. An encouraging 6.6-month median progression-free survival (PFS). A 66.7% disease control rate (DCR). A safety profile consistent with previously reported data when combined with anti-PD-1 monotherapy. T-cell responses to both IO102 (targeting IDO) and IO103 (targeting PD-L1) were detected after treatment. “These encouraging data further support the potential of IO102-IO103 in combination with pembrolizumab as first-line treatment for patients with recurrent or metastatic SCCHN including HPV-positive and -negative patients,” stated Jonathan Riess, MD, principal investigator of the trial and Director, Thoracic Oncology at the UC Davis Comprehensive Cancer Center. “Given the need for new treatment options that are effective, safe and accessible for head and neck cancer patients, further investigation of this combination should be conducted to build on the findings of this Phase 2 trial.” “With the data we’ve presented from studies in head and neck cancer and in melanoma, evidence is accumulating that the combination of IO102-IO103 with the anti-PD-1 therapy pembrolizumab could be a safe and efficacious first-line treatment for patients with a range of cancers, including those with metastatic and difficult-to-treat disease,” said Qasim Ahmad, MD, Chief Medical Officer of IO Biotech. “Importantly, with mPFS of 6.6 months, more than half of the patients in this trial had over 180 days of progression-free survival. These data are supportive of further investigation of this combination regimen as part of our commitment to transform the lives of cancer patients through our novel therapeutic vaccine.” The Phase 2 basket study (IOB-022/KN-D38; NCT05077709) is a non-comparative, open-label trial to investigate the safety and efficacy of IO102-IO103 in combination with pembrolizumab as a first-line treatment in up to 60 patients with metastatic non-small cell lung cancer (NSCLC) with PD-L1 TPS ≥ 50% and recurrent or metastatic SCCHN with PD-L1 CPS ≥ 20. The primary endpoint of the study is overall response rate. Patients enrolled in the study who had at least 2 post-baseline tumor assessments or who discontinued after 2 cycles of study treatment as of the data cut off of August 2, 2024 were considered efficacy evaluable and were included in the ESMO poster presentation. To date, the safety profile observed in this study (OB-022/KN-D38) is consistent with prior studies of IO102-IO103 in combination with checkpoint inhibitors, with no added significant systemic toxicity compared to anti-PD1 monotherapy and low-grade transient injection site reactions reported as the most common treatment related adverse events. The trial has completed enrollment of patients in all cohorts. Data from the non-small cell lung cancer (NSCLC) cohort of this study will also be presented at another medical meeting in the fall. The poster can be found on the “Posters & Publications” page of the IO Biotech website. Details for the presentation are below: Poster Title: A phase 2 trial of the IO102-IO103 vaccine plus pembrolizumab: completed cohort for first line (1L) treatment of advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Presentation number: 1022P Presenter: Jonathan W. Riess, MD, MS (UC Davis Comprehensive Cancer Center) Date: Saturday, September 14, 2024 Time: 12:00 PM – 1:00 PM CEST IO102-IO103 is an investigational off-the-shelf therapeutic cancer vaccine designed to kill both tumor cells and immune-suppressive cells in the tumor microenvironment (TME) by stimulating activation and expansion of T cells against indoleamine 2,3-dioxygenase (IDO) positive and programmed death-ligand 1 (PD-L1) positive cells. The company is currently conducting a pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) investigating IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with advanced melanoma, a Phase 2 basket trial (IOB-022/KN-D38; NCT05077709) investigating IO102-IO103 in combination with pembrolizumab as first line treatment in patients with solid tumors, and a Phase 2 basket trial (IOB-032/PN-E40; NCT05280314) investigating IO102-IO103 in combination with pembrolizumab as neo-adjuvant/adjuvant treatment of patients with solid tumors. The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. IOB-022/KN-D38 (NCT05077709) is a non-comparative, open-label trial to investigate the safety and efficacy of IO102-IO103 in combination with pembrolizumab in first-line advanced cancers in non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN). IO Biotech is sponsoring the Phase 2 trial and Merck is supplying pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103. IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target the immunosuppressive cells in the tumor microenvironment. IO Biotech is advancing its lead cancer vaccine candidate, IO102-IO103, in clinical trials, and additional pipeline candidates through preclinical development. Based on positive Phase 1/2 first line metastatic melanoma data, IO102-IO103, in combination with pembrolizumab, has been granted a breakthrough therapy designation for the treatment of advanced melanoma by the US Food and Drug Administration. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York. The content above comes from the network. if any infringement, please contact us to modify.

VaccineBreakthrough TherapyClinical Result

14 Sep 2024

·www.fiercebiotech.com

ESMO: IO Biotech's vaccine and Keytruda combo hits primary endpoint in phase 2 squamous cell carcinoma trial

Patients who received IO Biotech's vaccine with Keytruda experienced median progression-free survival of 6.6 months and a disease control rate of 66.7%. Immune checkpoint inhibitors are the superheroes of cancer therapy. Drugs like Bristol Myers Squibb’s Opdivo and Merck’s Keytruda are among the most profitable in the world—Keytruda pulled in $25 billion last year, making it the bestselling drug of 2023. But every good superhero needs a sidekick.During the 2024 European Society for Medical Oncology congress, Copenhagen-based IO Biotech presented data showing that its IO102-IO103 cancer vaccine, in combination with Keytruda (pembrolizumab), delivered an objective response rate of 44.4%, hitting the primary endpoint of a phase 2 trial in patients with advanced squamous cell carcinoma of the head and neck (SCCHN).“With the data we’ve presented from studies in head and neck cancer and in melanoma, evidence is accumulating that the combination of IO102-IO103 with the anti-PD-1 therapy pembrolizumab could be a safe and efficacious first-line treatment for patients with a range of cancers, including those with metastatic and difficult-to-treat disease,” IO Biotech's chief medical officer, Qasim Ahmad, M.D., said in a Sept. 14 release. IO Biotech’s IO102-IO103 vaccine is actually a combination of two vaccines that each prime patients’ T cells to target tumors. IO102 induces the immune cells to go after indoleamine-2,3-dioxygenase (IDO), an enzyme found inside of cells, while IO103 directs them toward programmed death-ligand 1 (PD-L1), a protein embedded in the cell membrane. Both IDO and PD-L1 are used by cancer cells to avoid being targeted and destroyed by the body’s immune system.By activating T cells against IDO and PD-L1, the theory is that the body’s immune system will join the fight against cancerous cells.The IOB-022/KN-D38 phase 2 trial had a total of 63 patients enrolled across cancer types as of Aug. 2, with 21 SCCHN patients enrolled. SCCHN patients who received the vaccine with Keytruda experienced median progression-free survival of 6.6 months and a disease control rate of 66.7%.Adverse events were common, with 20 of 21 patients experiencing side effects. Most were of low severity, like rash, fatigue and a reaction at the injection site. One patient suffered a severe treatment-related adverse event, immune thrombocytopenia, which was managed with corticosteroid treatment. Two patients discontinued treatment due to side effects of conjunctivitis and colitis, while another died of an unrelated illness during the trial. That left 18 patients for the data analysis.Data from the cohort of patients with non-small cell lung cancer will be presented at another meeting this fall, IO Biotech said in the release.Merck is collaborating on the IO102-IO103 trials, but IO Biotech maintains global commercial rights to the vaccines, according to the release. IO’s assets aren’t the only cancer vaccines Merck is auditioning for a supporting role alongside Keytruda. At the American Society of Clinical Oncology meeting in June, the Big Pharma shared data from a phase 2 trial of an mRNA vaccine being developed with Moderna. At a typical follow-up of 34.9 months, the vaccine and Keytruda combo reduced the risk of recurrence or death by 49% compared to Keytruda alone in patients with resected melanoma.IO Biotech raised a $155 million series B in 2021 to advance its cancer vaccines. The Danish company is also testing IO102-IO103 in combination with Opdivo (nivolumab) and BMS' relatlimab in a phase 2 trial in untreated, unresectable melanoma. The vaccine-Opdivo combo received a breakthrough-therapy designation from the FDA in 2020.Earlier this year at the World Vaccine Congress, Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research, expressed the agency’s willingness to review new cancer vaccines.

Clinical ResultVaccineBreakthrough TherapyPhase 2ASCO

09 Apr 2024

·www.globenewswire.com

IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103

Non-Clinical Poster Data Support the Use of Dual Antigen Approach to Enhance Anti-Tumor ActivityNEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today shared new data related to the company’s lead therapeutic cancer vaccine candidate, IO102-IO103, at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, California. “These data build on earlier studies that demonstrated the mechanism of IO102 and IO103,” said Mai-Britt Zocca, Ph.D., President and CEO of IO Biotech. “We now clearly see that used together, IO102-IO103 create an environment in and around the tumor that allow for enhanced anti-tumor activity, at a much greater level than either could do on its own. With this additional data, we further understand the mechanistic rationale for the clinical effect observed in the Phase 1/2 study of IO102-IO103 that we hope to confirm in our ongoing Phase 3 pivotal study.” The data presented in the AACR poster are from two different animal tumor models and show that vaccines targeting IDO1 and PD-L1 expressing cells can cooperatively reduce tumor growth with each contributing to the anti-tumor effect through distinct molecular pathways. Where high levels of IDO1 and PD-L1 expression were seen in the tumor microenvironment (TME), the IDO1 vaccine predominantly reduced myeloid-derived immune suppression, while the PD-L1 vaccine enhanced anti-tumor T-effector functions. In contrast, where IDO1 and PD-L1 expression was lower, the IDO1 vaccine resulted in a clear increase in T cell infiltration and activation and the PD-L1 vaccine impacted the myeloid cell compartment. While further studies are needed to fully discern the relationship between IDO1+/PD-L1+ target populations within the TME and the impact of IDO1/PD-L1 targeted vaccination, our data support the use of a dual antigen approach to reduce the immunosuppression and enhance anti-tumor effect. The poster can be found on the “Posters & Publications” page of the IO Biotech website and on the AACR website. Details for the presentation are below: Title: Immune modulatory cancer vaccines against IDO1 and PD-L1 trigger distinct pathways and cooperatively reduce tumor growth in preclinical models Abstract Number: 4094Time: Tuesday, April 9, 2024 9:00 AM - 12:30 PM PTPresenter: Marion Chapellier, Ph.D., Senior Scientist R&D and translational research About IO102-IO103 IO102-IO103 is an investigational, off-the-shelf therapeutic cancer vaccine designed to kill both tumor cells and immune-suppressive cells in the tumor microenvironment (TME) by stimulating activation and expansion of T cells against indoleamine 2,3-dioxygenase (IDO) and/or programmed death-ligand 1 (PD-L1) cells. The company is currently conducting a pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) investigating IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with advanced melanoma, a Phase 2 basket trial (IOB-022/KN-D38; NCT05077709) investigating IO102-IO103 in combination with pembrolizumab as first line treatment in patients with solid tumors, and a Phase 2 basket trial (IOB-032/PN-E40; NCT05280314) investigating IO102-IO103 in combination with pembrolizumab as neo-adjuvant/adjuvant treatment of patients with solid tumors. The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, and Merck is supplying pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. About the IOB-013/KN-D18 Pivotal Phase 3 Clinical Trial IOB-013/KN-D18 (Clinical Trials.gov: NCT05155254) is an open label, randomized Phase 3 clinical trial of IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable or metastatic (advanced) melanoma, being conducted in collaboration with Merck. Patients have been enrolled from centers across the United States, Europe, Australia, Turkey, Israel and South Africa. The primary endpoint of the study is progression free survival. Biomarker analyses will also be conducted. IO Biotech is sponsoring the Phase 3 trial and Merck is supplying pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103. About IO Biotech IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target the immunosuppressive cells in the tumor microenvironment. IO Biotech is advancing its lead cancer vaccine candidate, IO102-IO103, in clinical trials, and additional pipeline candidates through preclinical development. Based on positive Phase 1/2 first line metastatic melanoma data, IO102-IO103, in combination with pembrolizumab, has been granted a breakthrough therapy designation for the treatment of advanced melanoma by the US Food and Drug Administration. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York. For further information, please visit www.iobiotech.com. Follow us on our social media channels on LinkedIn and X (@IOBiotech). Forward-Looking Statement This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including regarding the timing of the interim and primary analyses of the company’s Phase 3 trial, current or future clinical trials, their progress, enrollment or results, or the company’s financial position or cash runway, are based on IO Biotech’s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise. Contact:Maryann Cimino, Director of Investor Relations IO Biotech, Inc.617-710-7305mci@iobiotech.com

VaccinePhase 3Phase 2Breakthrough Therapy

100 Deals associated with etimumotide

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Squamous Cell Carcinoma	Phase 2	US	The Johns Hopkins University	26 Dec 2020
Myeloproliferative Disorders	Phase 2	DK	University Hospital Maastricht	27 Jul 2019
Chronic Lymphocytic Leukemia	Phase 2	DK	Herlev Hospital	07 Apr 2019
Smoldering Multiple Myeloma	Phase 2	DK	IO Biotech ApS	18 Feb 2019
Smoldering Multiple Myeloma	Phase 2	DK	Herlev Hospital	18 Feb 2019
Basal Cell Carcinoma	Phase 2	DK	Herlev Hospital	01 Nov 2018
Melanoma	Phase 2	DK	Herlev Hospital	30 Jan 2018
Follicular Lymphoma	Phase 1	DK	Herlev Hospital	02 Jan 2018
Multiple Myeloma	Phase 1	DK	Herlev Hospital	01 Feb 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


WCLC2022	Not Applicable	-	43	PD-1 inhibitor	nyilggpfqd(nymxcggjln) = hqerwrmica jgfdtmijfp (infufynauv ) View more	-	06 Aug 2022
WCLC2022	Not Applicable	-	43	PD-L1 inhibitor	nyilggpfqd(nymxcggjln) = bulgreyhgg jgfdtmijfp (infufynauv ) View more	-	06 Aug 2022
NCT03714529 (Pubmed \| Cancers (Basel)) Manual	Phase 2	Basal Cell Carcinoma	10	IO103	gnsycflpnp(emxfwmttai) = 9/10 induced in blood samples and 5/9 in skin-infiltrating lymphocytes jcedqbhecu (lgpcdqiyco ) View more	Positive	22 Feb 2021
NCT03042793 (Pubmed \| Front Immunol) Manual	Phase 1	Multiple Myeloma	10	IO103	kaekanwgks(ggdxooickt) = below CTCAE grade 3, and most were grade 1-2 injection site reactions oaxwulzxsf (hscrkpgwlz )	Positive	09 Nov 2020
ASCO2015	Not Applicable	Thymic Epithelial Tumor	29	Chemotherapy	nqnztlcpjc(envlgycwgr) = kezhkourzm yenbvbyzzd (jppoaoxwgy )	-	20 May 2015

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

etimumotide

Overview

Basic Info

Gene Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation